Crosstalk between HER2 signaling and angiogenesis in breast cancer: Molecular basis, clinical applications and challenges

Current Opinion in Oncology

Volumn 25, Issue 3, 2013, Pages 313-324

  Alameddine, Raafat S ^a   Otrock, Zaher K ^b   Awada, Ahmad ^c   Shamseddine, Ali ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c JULES BORDET INSTITUTE   (Belgium)

Author keywords

angiogenesis; breast cancer; human epidermal growth factor receptor 2; vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CELECOXIB; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; DNA; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EVEROLIMUS; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NAVELBINE; PACLITAXEL; PANITUMUMAB; PAZOPANIB; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SUNITINIB; TRASTUZUMAB; VARLITINIB; VASCULOTROPIN;

ADVANCED CANCER; ANEUPLOIDY; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ASTHENIA; BRAIN METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR TOXICITY; CLINICAL TRIAL (TOPIC); COLON CANCER; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; GENE OVEREXPRESSION; HAND FOOT SYNDROME; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; LIVER METASTASIS; LUNG METASTASIS; METASTASIS; METRONOMIC DRUG ADMINISTRATION; MOLECULAR MECHANICS; NAUSEA; NEUTROPENIA; NONHUMAN; OPTIMAL DRUG DOSE; PANCREAS CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; THROMBOEMBOLISM; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; TUMOR SEEDING; UNSPECIFIED SIDE EFFECT; UPREGULATION;

ANIMALS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, ERBB-2;

EID: 84876286931     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32835ff362     Document Type: Review

References (107)

1. Otrock ZK, Mahfouz RA, Makarem JA, Shamseddine AI. Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cells Mol Dis 2007; 39:212-220.
2. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2:795-803.
3. Folkman J, Aldrighetti D, Zucchinelli P, et al. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
4. Giovannini M, Aldrighetti D, Zucchinelli P, et al. Antiangiogenic strategies in breast cancer management. Crit Rev Oncol Hematol 2010; 76:13-35.
5. Miller KD, Dul CL. Breast cancer: the role of angiogenesis and antiangiogenic therapy. Hematol Oncol Clin North Am 2004; 18:1071-1086.
6. Guinebretiere JM, Le Monique G, Gavoille A, et al. Angiogenesis and risk of breast cancer in women with fibrocystic disease. J Natl Cancer Inst 1994; 86:635-636.
7. Schneider BP, Miller KD. Angiogenesis of breast cancer. J Clin Oncol 2005; 23:1782-1790.
8. Brem S, Gullino P, Medina D. Angiogenesis: a marker for neoplastic transformation of mammary papillary hyperplasia. Science 1977; 195: 880-882.
9. Jensen H, Chen I, DeVault M, Lewis A. Angiogenesis induced by "normal" human breast tissue: a probable marker for precancer. Science 1982; 218:293-295.
10. Guinebretière JM, Lê Monique G, Gavoille A, et al. Angiogenesis and risk of breast cancer in women with fibrocystic disease. J Natl Cancer Inst 1994; 86:635-636.
11. Guidi AJ, Fischer L, Harris JR, Schnitt SJ. Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst 1994; 86:614-619.
12. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-752.
13. Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 2000; 19:6115-6121.
14. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-182.
15. Liao N, Zhang GC, Liu YH, et al. HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component. Pathol Res Pract 2011; 207:1-7.
16. Davies E, Hiscox S. New therapeutic approaches in breast cancer. Maturitas 2011; 68:121-128.
17. Wright C, Nicholson S, Angus B, et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992; 65:118-121.
18. Kallioniemi OP, Holli K, Visakorpi T, et al. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 1991; 49:650-655.
19. Qian X, O'Rourke DM, Zhao H, Greene MI. Inhibition of p185neu kinase activity and cellular transformation by co-expression of a truncated neu protein. Oncogene 1996; 13:2149-2157.
20. Callahan R, Hurvitz S. Human epidermal growth factor receptor-2-positive breast cancer: current management of early, advanced, and recurrent disease. Curr Opin Obstet Gynecol 2011; 23:37-43.
21. Burgess AW, Cho HS, Eigenbrot C, et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003; 12:541-552.
22. Roskoski R Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004; 319:1-11.
23. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103:211-225.
24. Neve RM, Holbro T, Hynes NE. Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells. Oncogene 2002; 21:4567-4576.
25. Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 2003; 284:54-65.
26. Carraway KL 3rd, Sliwkowski MK, Akita R, et al. The erbB3 gene product is a receptor for heregulin. J Biol Chem 1994; 269:14303-14306.
27. Klapper LN, Glathe S, Vaisman N, et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA 1999; 96:4995-5000.
28. Sliwkowski MX, Schaefer G, Akita RW, et al. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 1994; 269:14661-14665.
29. Troyer KL, Lee DC. Regulation of mouse mammary gland development and tumorigenesis by the ERBB signaling network. J Mammary Gland Biol Neoplasia 2001; 6:7-21.
30. Harris RC, Chung E, Coffey RJ. EGF receptor ligands. Expl Cell Res 2003; 284:2-13.
31. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004; 59 (2 Suppl):21-26.
32. Rowinsky EK. The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu Rev Med 2004; 55:433-457.
33. Beerli RR, Hynes NE. Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities. J Biol Chem 1996; 271:6071-6076.
34. Laughner E, Taghavi P, Chiles K, et al. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1a (HIF-1a) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001; 21:3995-4004.
35. Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997; 151:1523-1530.
36. Yen L, You XL, Al Moustafa AE, et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 2000; 19:3460-3469.
37. Pegram MD, Reese DM. Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. Semin Oncol 2002; 29 (3 Suppl 11):29-37.
38. Ludovini V, Sidoni A, Pistola L, et al. Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients. Breast Cancer Res Treat 2003; 81:159-168.
39. Xiong S, Grijalva R, Zhang L, et al. Up-regulation of vascular endothelial growth factor in breast cancer cells by the heregulin-(1-activated p38 signaling pathway enhances endothelial cell migration. Cancer Res 2001; 61:1727-1732.
40. Klos KS, Wyszomierski SL, Sun M, et al. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res 2006; 66:2028-2037.
41. Konecny GE, Meng YG, Untch M, et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004; 10:1706-1716.
42. Wang S-C, Lien H-C, Xia W, et al. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 2004; 6:251-261.
43. Wang YN, Yamaguchi H, Hsu JM, Hung MC. Nuclear trafficking of the epidermal growth factor receptor family membrane proteins. Oncogene 2010; 29:3997-4006.
44. Giri DK, Ali-Seyed M, Li L-Y, et al. Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor. Mol Cell Biol 2005; 25:11005-11018.
45. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93:705-716.
46. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 2000; 19:19-27.
47. Chang S-H, Liu CH, Conway R, et al. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci USA 2004; 101:591-596.
48. Wang D, DuBois RN. Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch. Proc Natl Acad Sc USA 2004; 101: 415-416.
49. Subbaramaiah K, Norton L, Gerald W, Dannanberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer. J Biol Chem 2002; 277:18649-18657.
50. Howe LR, Chang S-H, Tolle KC, et al. HER2/neu-Induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res 2005; 65:10113-10119.
51. Hanahan D, Robert A. Weinberg, hallmarks of cancer: the next generation. Cell 2011; 144:646-674.
52. Wen XF, Yang G, Mao W, et al. HER2 signaling modulates the equilibrium between pro-and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 2006; 25:6986-6996.
53. Le XF, Mao W, Lu C, et al. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that over-express HER2. Cell Cycle 2008; 7:3747-3758.
54. Kim EM, Lobocki C, Dubay L, Mittal VK. A specific vascular endothelial growth factor receptor tyrosine kinase inhibitor enhances the antiproliferative effect of trastuzumab in human epidermal growth factor receptor 2 over-expressing breast cancer cell lines. Am J Surg 2009; 197:331-336.
55. Izumi Y, Xu L, Tomaso E, et al. Tumour biology: herceptin acts as an antiangiogenic cocktail. Nature 2002; 416:279-280.
56. Farhat MH, El-Saghir NS, Shamseddine AI. Modified resistance to chemotherapy and trastuzumab by bevacizumab in locally recurrent breast cancer. Breast 2009; 18:66-68.
57. Raefsky E, Castillo R, Lahiry A, et al. Phase II study of neoadjuvant bevacizumab and trastuzumab administered with albumin-bound paclitaxel (nab paclitaxel) and carboplatin in HER2+ locally advanced breast cancer. ASCO Meeting Abstracts 2008; 26 (15 suppl):627.
58. Smith JW, Buyse M, Rastogi P, et al. Epirubicin plus cyclophosphamide followed by docetaxel plus trastuzumab and bevacizumab as neoadjuvant therapy for HER2-positive locally advanced breast cancer (LABC) or as adjuvant therapy for HER2-positive pathologic stage III breast cancer (PS3BC): A phase II trial of the NSABP Foundation Research Group. ASCO Meeting Abstracts 2009; 27 (15S):580.
59. Foy KC, Liu Z, Phillips G, Miller M. Combination treatment with HER-2 and VEGF peptide mimics induces potent antitumor and antiangiogenic responses in vitro and in vivo. J Biol Chem 2011; 286:13626-13637.
60. Yardley DA, Raefsky E, Castillo R, et al. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer. Clin Breast Cancer 2011; 11:297-305.
61. Pierga JY, Petit T, Delozier T, et al. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. Lancet Oncol 2012;13:375-384.
62. Rugo HS, Jo Chien A, Franco SX, et al. A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 2011; 24:24.
63. Martin M, Makhson A, Gligorov J, et al. Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer. Oncologist 2012; 17:469-475.
64. Gianni L, Romieu G, Lichinitser M, et al. S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC). Cancer Res 2012; 71 (Suppl 24):S4-S8.
65. Cardoso F, Canon JL, Amadori D, et al. An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer. Breast 2012; 21: 716-723.
66. Cristofanilli M, Johnston SRD, Manikhas A, et al. A randomized phase II study (VEG108838) of lapatanib plus pazopanib (L+P) versus lapatanib (L) in patients with ErbB2+ inflammatory breast cancer (IBC). ASCO Meeting Abstracts 2012; 30 (Suppl 15):531.
67. Gasparini G. Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2001; 2:733-740.
68. Liggett SB. Pharmacogenetic applications of the Human Genome project. Nat Med 2001; 7:281-283.
69. Gately S, Kerbel R. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J 2001; 7:427-436.
70. Presta M, Rusnati M, Belleri M, et al. Purine analogue 6-methylmercapto-purine riboside inhibits early and late phases of the angiogenesis process. Cancer Res 1999; 59:2417-2424.
71. Vacca A, Iurlaro M, Ribatti D, et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 1999; 94:4143-4155.
72. Kamen BA, Rubin E, Aisner J, Glastein E. High-time chemotherapy or high time for low dose. J Clin Oncol 2000; 18:2935-2937.
73. Seidman AD, Hudis CA, Albanelll J, et al. Dose-dense therapy with weekly 1-h paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998; 16:3353-3361.
74. du Manoir JM, Francia G, Man S, et al. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res 2006; 12: 904-916.
75. Orlando L, Caedillo A, Ghisini R, et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 2006; 6:225.
76. Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 2010; 40:310-322.
77. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18:1926-1945.
78. Kobayashi S, Kishimoto T, Kamata S, et al. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci 2007; 98:726-733.
79. Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006; 12:122-127.
80. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372:449-456.
81. McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011; 364:1595-1606.
82. Morrow PK, Wulf GM, Ensor J, et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpres-sing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 2011; 29:3126-3132.
83. Wei D, Wang L, He Y, et al. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res 2004; 64:2030-2038.
84. Xia W, Zhao T, Lv J, et al. Celecoxib enhanced the sensitivity of cancer cells to anticancer drugs by inhibition of the expression of P-glycoprotein through a COX-2-independent manner. J Cell Biochem 2009; 108:181-194.
85. Dang CT, Dannenberg AJ, Subbaramaiah K, et al. Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clin Cancer Res 2004; 10:4062-4067.
86. Miller K, Wang M, Gralow J. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-2676.
87. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29:1252-1260.
88. Pivot X, Schneeweiss A, Verma S, et al. Efficacy and safety ofbevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: Results from AVADO. Eur J Cancer 2011; 47:2387-2395.
89. D'Agostino RB Sr. Changing end points in breast-cancer drug approval: the Avastin story. N Engl J Med 2011; 365:e2.
90. Cameron D, Brown J, Dent R, et al. Primary results of BEATRICE, a randomized phase III trial evaluating adjuvant bevacizumab-containing therapy in triple-negative breast cancer. Cancer Res 2012; 72 (Suppl 24):S6-5.
91. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15:232-239.
92. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-231.
93. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8:299-309.
94. Du R, Lu KV, Petritsch C, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008; 13:206-220.
95. Darland DC, Massingham LJ, Smith SR, et al. Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev Biol 2003; 264:275-288.
96. Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111:1287-1295.
97. Rubenstein JL, Kim J, Ozawa T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000; 2:306-314.
98. Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57:963-969.
99. Shojaei F, Wu X, Malik AK, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 2007; 25:911-920.
100. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360:563-572.
101. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27:672-680.
102. Saltz LB, Lenz H-J, Kindler HL, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 Study. J Clin Oncol 2007; 25:4557-4561.
103. Punt CJA, Tol J. More is less-combining targeted therapies in metastatic colorectal cancer. Nat Rev Clin Oncol 2009; 6:731-733.
104. Larsen AK, Ouaret D, El Ouadrani K, Petitprez A. Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis. Pharmacol Therap 2011; 131:80-90.
105. Choueiri TK, Mayer EL, Je Y, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 2011; 29:632-638.
106. Hawkes EA, Okines AF, Plummer C, Cunningham D. Cardiotoxicity in patients treated with bevacizumab is potentially reversible. J Clin Oncol 2011; 29:e560-e562.
107. Criscitiello C, Matzger-Filho O, Saini KS, et al. Targeted therapies in breast cancer: are heart and vesselsalso being targeted? Breast Cancer Res 2012; 14:209.